Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
For an adolescent with bacterial meningitis and subsequent cerebral aspergillosis, intravenous voriconazole dose requirements substantially decreased during coadministration with intravenous chloramphenicol and considerably rose after discontinuation of the antibiotic. In agreement with in vitro evidence, these data suggest that chloramphenicol is a rather significant inhibitor of hepatic CYP3A4 and/or CYP2C19.
Hafner
Verena
V
Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Albermann
Nadine
N
Haefeli
Walter E
WE
Ebinger
Friedrich
F
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors; D002701:Chloramphenicol / Q000008:administration & dosage / Q000009:adverse effects*; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D020953:Neuroaspergillosis / Q000188:drug therapy* / Q000378:metabolism*; D011743:Pyrimidines / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D014230:Triazoles / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D065819:Voriconazole
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D011743:Pyrimidines; D014230:Triazoles; D002701:Chloramphenicol; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D065819:Voriconazole
Transplant Proc. 2000 May;32(3):660-2
10812156
Curr Opin Crit Care. 2007 Oct;13(5):592-7
17762241
N Engl J Med. 2002 Aug 8;347(6):408-15
12167683
Pediatr Infect Dis J. 2002 Mar;21(3):240-8
12005089
Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72
15155217
Transplantation. 2006 Feb 15;81(3):320-6
16477215
Arch Dis Child. 2008 Jul;93(7):578-81
18252755
Clin Pharmacol Ther. 1978 Nov;24(5):571-5
699481
Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2
16569888
Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9
14576103
Drug Metab Dispos. 1987 Nov-Dec;15(6):852-6
2893713
Pediatr Blood Cancer. 2007 Aug;49(2):203-7
16333861
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:56-61
14616415
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:51-5
14616414
Br J Clin Pharmacol. 2002 Dec;54(6):635-42
12492612
Transpl Infect Dis. 2002 Sep;4(3):169-74
12421465
Eur J Clin Pharmacol. 2000 Aug;56(5):395-8
11009048
J Pharmacol Exp Ther. 1984 Oct;231(1):80-4
6491977
Clin Pharmacol Ther. 2005 Jul;78(1):25-33
16003289
Mol Pharmacol. 1985 Sep;28(3):290-6
4033629
Transplantation. 1998 May 27;65(10):1397-8
9625026
Drug Metab Dispos. 2003 May;31(5):540-7
12695341